Total submissions: 21
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Pharm |
RCV001847567 | SCV002031239 | drug response | methotrexate response - Toxicity | 2021-03-24 | reviewed by expert panel | curation | PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications. |
Eurofins Ntd Llc |
RCV000153516 | SCV000203040 | other | not provided | 2017-01-13 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000428048 | SCV000519504 | benign | not specified | 2016-04-25 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
ARUP Laboratories, |
RCV000153516 | SCV000884146 | uncertain significance | not provided | 2023-11-29 | criteria provided, single submitter | clinical testing | The MTHFR c.665C>T; p.Ala222Val variant (rs1801133), also known as C677T or the thermolabile variant, is listed in the ClinVar database (Variation ID: 3520) and is observed in the general population with an overall allele frequency of 30.8% (87,234/282,784 alleles including 15,819 homozygotes) in the Genome Aggregation Database. The thermolabile c.665C>T variant in the homozygous state has been correlated with reduced enzyme activity and increased homocysteine (Frosst 1995). The practice guidelines from The American College of Medical Genetics state that this variant in the heterozygous state is unlikely to be of clinical significance (Hickey 2013); however, a possible effect of this variant when paired with a pathogenic MTHFR variant on the opposite chromosome cannot be excluded. Additionally, the practice guidelines state that an individual who is homozygous for the c.665C>T; p.Ala222Val variant and has elevated homocysteine may be at mildly increased risk for venous thromboembolism and recurrent pregnancy loss (Hickey 2013). The variant is considered a ''susceptibility'' or an ''association'' variant. REFERENCES Frosst P et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111-3. PMID: 7647779. Hickey SE et al. ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing. Genet Med. 2013 Feb;15(2):153-6. PMID: 23288205. |
Mendelics | RCV000259890 | SCV001135171 | likely benign | Neural tube defects, folate-sensitive | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000153516 | SCV001147149 | uncertain significance | not provided | 2024-01-01 | criteria provided, single submitter | clinical testing | MTHFR: PM3, PM2:Supporting |
Myriad Genetics, |
RCV001030751 | SCV001194043 | pathogenic | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2019-12-16 | criteria provided, single submitter | clinical testing | NM_005957.4(MTHFR):c.665C>T(A222V) is a common variant present in approximately 30% of the general population. While many individuals who are homozygous for this variant are asymptomatic, some may have mild MTHFR deficiency associated with increased plasma homocysteine. Sources cited for classification include the following: PMID 7647779, 8837319, 9545406, 11781870, 12560871, 8903338, 9789068, 11929966, 15565101, 17436239, 12356947, 9133512, 12196644 and 9798595. Classification of NM_005957.4(MTHFR):c.665C>T(A222V) is based on the following criteria: This is a well-established variant in the literature that has been observed more frequently in patients with mild MTHFR deficiency than in healthy populations and there is functional data showing deficient protein function. Please note: this variant was assessed in the context of healthy population screening. |
Centre for Mendelian Genomics, |
RCV001030751 | SCV001366606 | pathogenic | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2019-01-17 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: No criteria apply. This variant was detected in homozygous state. |
Labcorp Genetics |
RCV001030751 | SCV001733273 | benign | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV004584309 | SCV002506425 | uncertain significance | See cases | 2022-01-06 | criteria provided, single submitter | clinical testing | ACMG categories: PS3,PS4,PM1,BA1 |
OMIM | RCV000003697 | SCV000023860 | benign | MTHFR THERMOLABILE POLYMORPHISM | 2023-09-29 | no assertion criteria provided | literature only | |
Firma |
RCV000003697 | SCV000106043 | pathogenic | MTHFR THERMOLABILE POLYMORPHISM | no assertion criteria provided | clinical testing | ||
Department of Pharmacy and Biotechnology, |
RCV000144921 | SCV000187678 | uncertain significance | Gastrointestinal stromal tumor | no assertion criteria provided | case-control | ||
Database of Curated Mutations |
RCV000427078 | SCV000505736 | not provided | Neoplasm of stomach | 2016-03-10 | no assertion provided | literature only | |
Department Of Genetics, |
RCV000761447 | SCV000891532 | uncertain significance | Thrombophilia due to thrombin defect | 2017-12-30 | no assertion criteria provided | curation | |
Neurology Department, |
RCV001030751 | SCV001423141 | uncertain significance | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2020-04-23 | no assertion criteria provided | research | |
Natera, |
RCV001030751 | SCV001463167 | benign | Homocystinuria due to methylene tetrahydrofolate reductase deficiency | 2019-12-07 | no assertion criteria provided | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000428048 | SCV001549379 | benign | not specified | no assertion criteria provided | clinical testing | ||
Clinical Genetics, |
RCV000428048 | SCV001917884 | benign | not specified | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000428048 | SCV001930296 | benign | not specified | no assertion criteria provided | clinical testing | ||
i |
RCV000259890 | SCV002538647 | likely benign | Neural tube defects, folate-sensitive | no assertion criteria provided | reference population |